Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc.
Your view on IMDX
Overview
What the company does, where it operates, and who runs it.
About Insight Molecular Diagnostics Inc.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Joshua Riggs
- Headquarters
- US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Joshua Riggs
- Headquarters
- US
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.
It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.
The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Insight Molecular Diagnostics Inc., and the rating behind it. IMDX last traded at $4.20; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Insight Molecular Diagnostics Inc.. Starting points for Insight Molecular Diagnostics Inc.: EPS -$1.34, beta 1.80 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Insight Molecular Diagnostics Inc.. Insight Molecular Diagnostics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Insight Molecular Diagnostics Inc.. Trailing twelve-month EPS for Insight Molecular Diagnostics Inc. stands at -$1.34. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Insight Molecular Diagnostics Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Insight Molecular Diagnostics Inc. valued side by side against its closest peers. Insight Molecular Diagnostics Inc. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Insight Molecular Diagnostics Inc., and how their positions are changing. At a $135.6M market value, institutional positions materially move Insight Molecular Diagnostics Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Insight Molecular Diagnostics Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Insight Molecular Diagnostics Inc.. Insight Molecular Diagnostics Inc. is a $135.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Insight Molecular Diagnostics Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Insight Molecular Diagnostics Inc.. Coverage tracks Insight Molecular Diagnostics Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.